You are here » Home » Companies » Company Overview » Take Solutions Ltd

Take Solutions Ltd.

BSE: 532890 Sector: IT
NSE: TAKE ISIN Code: INE142I01023
BSE 00:00 | 24 Apr Take Solutions Ltd
NSE 05:30 | 01 Jan Take Solutions Ltd
OPEN 62.20
PREVIOUS CLOSE 63.00
VOLUME 4476
52-Week high 159.30
52-Week low 37.15
P/E
Mkt Cap.(Rs cr) 891
Buy Price 59.85
Buy Qty 138.00
Sell Price 60.25
Sell Qty 1900.00
OPEN 62.20
CLOSE 63.00
VOLUME 4476
52-Week high 159.30
52-Week low 37.15
P/E
Mkt Cap.(Rs cr) 891
Buy Price 59.85
Buy Qty 138.00
Sell Price 60.25
Sell Qty 1900.00

Take Solutions Ltd. (TAKE) - Chairman Speech

Company chairman speech

I am pleased to report the performance of the Company for 2018-19. Your Company crossedH2000 crores in revenues for the first ever time finishing the year with H2039 croresa creditable 28.5% growth over the previous financial year in rupee terms and a 19%growth in dollar terms. This growth in our revenues outperformed the growth of the globalLife Sciences sector. I am pleased that the growth in our EBITDA matched the high growthin our revenues indicating that we were focused on margins while scaling our business.The result is that the Company reported an unadjusted EBITDA of H3942 million during theyear under review representing a 26% growth over the previous year that translates to anadjusted EBITDA of H4280 millions in 2018-19 a growth in excess of 36% over the previousyear. The principal point that I wish to communicate is that the Company sustained itsgrowth in revenues and profits on account of the business-strengthening initiatives of theearlier years that now came to fruition.

Aligned to that commitment your Company acquired two companies during the year underreview with the objective to sustain its momentum. Your Company acquired US basedbusinesses Dataceutics Holdings Inc and KAI Holdings Inc during the year under review; andamalgamated into the TAKE system.

These acquisitions will strengthen the Company's global presence across the foreseeablefuture. The acquisition of the high-end data sciences company Dataceutics Holdings Incwill strengthen our clinical data services offerings. Besides the acquisition of KAIHoldings Inc expanded our CRO footprint in USA. We believe that these acquisitions areearnings-accretive and will strengthen our competitiveness across the foreseeable future.

Your company reinforced its business through forward-looking investments ininfrastructure. Your Company expanded its operational capacity by moving to largerfacilities in Princeton and Bengaluru; in addition your Company inaugurated a new dossierprinting facility in Chennai. Your Company deepened its commitment to invest in talenttechnology intellectual property and platforms. Your Company added six senior leaders tothe global team enhanced three technology IPs (including pharmaREADY and traceREADY)built additional capabilities around OneClinical our proprietary eClinical platformdeepened its Nets offerings and developed 16 bio-analytical methods. The result is thatyour Company finished the year under review with a stronger business model and optimism toaddress the challenges of the future.

Our strategic outlook

We aspire to be a USD 500 million company by 2021. This is eminently achievable fromthe Company achieving 20% growth over the next couple of years. The growth will getsupport from the revenue coming in from the recent acquisitions. Your Company has chartedout a strategic direction to grow faster even as it gets larger. Your Company intends toleverage its unique personality of a full-service CRO and technology-led life sciencesservices provider. It possesses expertise in full service clinical trial management anddata sciences offered through platform-driven clinical regulatory and safety solutionsand services. Your Company possesses the competence to help customers bring lifesavingdrugs to the market with speed and effectiveness.

Prognosis

Your Company intends to achieve greater operating efficiency. It plans to develop andexpand its clinical vertical as a critical growth engine. It is positioned to strengthenits regulatory and safety/PV businesses.

The complement of these initiatives is expected to strengthen our customer proposition.Besides as we grow in scale we expect to strengthen our terms of trade that helpmoderate our receivables cycle across the foreseeable future.

We expect that the combination of a multi-year engagement with some of the world'sprominent pharmaceutical clients superior trade terms cost management and superiorknowledge leverage should translate into a compelling volume cum value proposition thatenhances margins surplus and value in the hands of our shareholders.

Srinivasan H R

Vice Chairman and Managing Director